Donoghue Forlines’s NovoCure NVCR Stock Holding History

Donoghue Forlines’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-8,708	Closed	-$721K	–	280
2022 Q1	$721K	Buy	8,708 +2,643	+44%	+$195K	0.16%	219
2021 Q4	$455K	Buy	6,065 +764	+14%	+$76.7K	0.08%	242
2021 Q3	$616K	Buy	5,301 +1,118	+27%	+$169K	0.12%	174
2021 Q2	$928K	Sell	4,183 -339	-7%	-$65.9K	0.17%	141
2021 Q1	$598K	Buy	4,522 +275	+6%	+$43.5K	0.12%	173
2020 Q4	$735K	Buy	+4,247	New	+$581K	0.14%	176
2019 Q4	–	Sell	-30,856	Closed	-$2.31M	–	190
2019 Q3	$2.31M	Buy	+30,856	New	+$2.47M	0.33%	111

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Donoghue Forlines's NVCR Position: Q2 2022 in Review

Donoghue Forlines sold out of NovoCure (NVCR) in Q2 2022, closing a stake of 8,708 shares — an estimated $721K sold.

Donoghue Forlines first reported a position in NVCR in Q3 2019 and held it in 7 quarters. The position peaked at $2.31M in Q3 2019. 316 funds tracked by Wall St. Rank hold NVCR as of Q2 2022.

Donoghue Forlines reported no remaining NovoCure position as of Q2 2022 after selling out during the quarter.
Donoghue Forlines sold 8,708 NovoCure shares in Q2 2022, an estimated $721K.
Donoghue Forlines first reported a position in NovoCure in Q3 2019 and held it in 7 quarters.
Donoghue Forlines's NovoCure position peaked at $2.31M in Q3 2019.
316 funds tracked by Wall St. Rank held NovoCure as of Q2 2022.

Based on Donoghue Forlines's 13F filing for Q2 2022, filed 8 Aug 2022.